Avicenna journal of phytomedicine
Evaluation of the preventive effect of intravenous trans-sodium crocetinate followed by oral crocetin on contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angioplasty: A randomized placebo-controlled triple-blind clinical trial
By Salari S, Mohammadpour A, Gholoobi A and 4 others.
Abstract
Objective
Contrast media (CM) can potentially cause nephropathy. Trans-sodium crocetinate (TSC) has shown promising antioxidant and anti-inflammatory properties in animal studies. This research sought to assess TSC efficacy in contrast-induced nephropathy (CIN) prevention.
Materials and methods
A randomized triple-blind trial involving 130 patients undergoing elective PCI (percutaneous coronary intervention) was conducted. Participants received either TSC (0.5 mg/kg) before the procedure, followed by crocetin tablets thrice daily for five days to evaluate its impact on CIN occurrence, or a placebo. The primary outcome was the occurrence of CIN, with secondary outcomes including blood urea nitrogen (BUN), serum creatinine (SCr), glomerular filtration rate (GFR), C-reactive protein (CRP), urine albumin-to-creatinine ratio (ACR), and prooxidant-antioxidant balance (PAB) test in a 5-day follow-up.